

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62264

**Manuscript Type:** CASE REPORT

**S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report**

STEM chemotherapy for NECB

**Abstract**

**BACKGROUND**

Neuroendocrine carcinoma of the breast (NECB) is a rare type of malignant tumour. Due to the rarity of NECB, the relevant literature mostly comprises case reports. Available data on treatment options for NECB are very limited

**CASE SUMMARY**

**Match Overview**

1	Internet 41 words crawled on 11-Apr-2020 <a href="http://www.mdpi.com">www.mdpi.com</a>	2%
2	Internet 41 words crawled on 05-Mar-2021 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	2%
3	Crossref 34 words Fernando Collado-Mesa, Jose M. Net, Geetika A. Klevos, Monica M. Yepes. "Primary neuroendocrine carcinoma of th ...	1%
4	Internet 16 words crawled on 15-Apr-2021 <a href="http://clinicaltrials.gov">clinicaltrials.gov</a>	1%
5	Crossref 14 words Anna Koumarianou, Gregory Kaltsas, Matthew H. Kulke, Kjell Oberg et al. "Temozolomide in Advanced Neuroendocr ...	1%
6	Crossref Posted Content 14 words Özlem Özdemir, Baha Zengel, Yaşar Yıldız, Seray Saray et al. "Neuroendocrine Differentiated Breast Cancer Cases: ...	1%
7	Crossref 13 words Lena Marinova, Doroteya Malinova, Snezhinka Vicheva. "Pri mary Neuroendocrine Carcinoma of the Breast: Histopath ...	1%
8	Internet 13 words crawled on 21-Aug-2020	1%



ALL

IMAGES

VIDEOS

10,400 Results

Any time ▾

## Second-line treatment in patients with advanced extra ...

<https://journals.sagepub.com/doi/10.1177/1758835920915299>

Second-line therapy for patients with advanced EP-PD-NEC had limited efficacy in this meta-analysis, and a high Ki-67 was associated with treatment outcomes, as reported previously. 9,42 Indeed, the...

Cited by: 1

Author: Mairéad G McNamara, Melissa Frizziero,...

Publish Year: 2020

## Successful treatment with temozolomide in an elderly ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320007>

There have been few reported cases of pulmonary large-cell neuroendocrine tumor accompanied by abdominal lymph node metastasis. The treatment of temozolomide (TMZ) in advanced stage...

Author: Juan Wei, Xiao Fang Dong, Zu Liang ...

Publish Year: 2018

### PEOPLE ALSO ASK

Is it safe to take temozolomide with capecitabine? ▾

Can chemo prolong neuroendocrine tumors? ▾

When was the first classification of neuroendrine Tumors published? ▾

Is there a treatment for metastatic neuroendocrine tumor? ▾

Feedback

## (PDF) Temozolomide as Second or Third Line Treatment of ...

<https://www.researchgate.net/publication/230843763...>

Temozolomide is commonly used in the second-line setting. Temozolomide was given with or without capecitabine and bevacizumab as second-line treatment after cisplatin-based chemotherapy i...

## (PDF) Second-line treatment in patients with advanced ...

<https://www.researchgate.net/publication/340955962...>

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis April 2020 Therapeutic Advanc...

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

11,200 Results

Any time ▾

### [Metronomic temozolomide as second line treatment for ...](#)

[europepmc.org/articles/PMC4855772](https://europepmc.org/articles/PMC4855772) ▾

May 03, 2016 · Few prospective studies that investigate a **second line chemotherapy** in **neuroendocrine tumors** are available. In 2011 Welin et al. showed that **Temozolomide** may be an active, well tolerated, **second-line chemotherapy** regimen for NEC patients (mainly gastrointestinal) who have progressed after first-line **chemotherapy**. It seems to be effective also in lung **carcinoid**.

Cited by: 11

Author: C. De Divitiis, C. von Arx, A. M. Grimaldi, D. ...

Publish Year: 2016

### [\(PDF\) Temozolomide as Second or Third Line Treatment of ...](#)

<https://www.researchgate.net/publication/230843763...>

There are, however, no published studies concerning **second-line treatment of the disease**. **Temozolomide** has shown clinical effect in well-differentiated endocrine carcinomas.

### [Second-line treatment in patients with advanced extra ...](#)

<https://journals.sagepub.com/doi/10.1177/1758835920915299>

Apr 27, 2020 · **Second-line** therapy for patients with advanced EP-PD-NEC had limited efficacy in this meta-analysis, and a high Ki-67 was associated with **treatment** outcomes, as reported previously. 9,42 Indeed, the relevance of the proliferation marker Ki-67 in **neuroendocrine** tumours has long been reflected in the classification system, 43 and is also known to ...

Cited by: 2

Author: Mairéad G McNamara, Melissa Frizziero, Ti...

Publish Year: 2020

Estimated Reading Time: 9 mins

### [Phase II study of temozolomide monotherapy in patients ...](#)

<https://europepmc.org/article/PMC/PMC8088944> ▾

Mar 12, 2021 · Extrapulmonary **neuroendocrine carcinoma** (EPNEC) is a lethal disease with a poor prognosis. Platinum-based chemotherapy is used as the standard first-line **treatment** for unresectable EPNEC. Several retrospective studies have reported the results of the utilization of **temozolomide** (TMZ) as a drug for the **second-line treatment** for EPNEC.

Cited by: 1

Author: Noritoshi Kobayashi, Yuma Takeda, Naoki ...

Publish Year: 2021

### [\[PDF\] Neuroendocrine Carcinoma of the Stomach: A Response to ...](#)

<https://www.integ-jet.go.jp/article/internalmedicine/57/5/57-0260-171.pdf/ober/en>



ALL

IMAGES

VIDEOS

122,000 Results

Any time ▾

## Metronomic temozolomide as second line treatment for ...

[europepmc.org/articles/PMC4855772](https://europepmc.org/articles/PMC4855772) ▾

May 03, 2016 · Few prospective studies that investigate a **second line chemotherapy** in **neuroendocrine tumors** are available. In 2011 Welin et al. showed that **Temozolomide** may be an active, well tolerated, **second-line chemotherapy** regimen for NEC patients (mainly gastrointestinal) who have progressed after first-line **chemotherapy**. It seems to be effective also in lung **carcinoid**.

Cited by: 11

Author: C. De Divitiis, C. von Arx, A. M. Grimaldi, D. ...

Publish Year: 2016

## (PDF) Temozolomide as Second or Third Line Treatment of ...

<https://www.researchgate.net/publication/230843763...>

There are, however, no published studies concerning **second-line treatment of the disease**. **Temozolomide** has shown clinical effect in well-differentiated endocrine carcinomas.

## Temozolomide as Second or Third Line Treatment of Patients ...

<https://www.hindawi.com/journals/tswj/2012/170496> ▾

**Abstract**

Introduction

Material and Methods

Results

Discussion

Background. Knowledge of the clinical efficacy in recurrent **neuroendocrine carcinomas** is sparse. Treatment with **temozolomide** alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with **neuroendocrine carcinomas** (Ki-67 proliferation index >20%) and performance status 0–2 treated with **temozolomide** 200 mg/leg orally days 1–5 every 28 days after at least one previous platinum-containing chemotherapy regime